FACTORS PREDICTING MORTALITY OF PNEUMONIA DUE TO SARS-COV-2 IN DIABETES PATIENTS

Hoàn Lê, Thu Thảo Đỗ

Main Article Content

Abstract

Objective: Investigate some factors affecting mortality rate in patients with pneumonia caused by SARS-COV-2 and diabetes. Research subjects and methods: The cross-sectional, retrospective descriptive study was conducted on 242 patients with SARS-COV-2 pneumonia and diabetes from November 2021 to April 2022. Results and conclusion: the average age in the study was 72,7. The mortality rate in the SARS-COV-2 pneumonia group with diabetes for 10 years or more is higher than the group for less than 5 years and the group for 5-10 years. The mortality rate in the group with HbA1C > 6,5% was 73,7%, higher than the group with HbA1C ≤ 6,5%. The group with severe and critical pneumonia has a mortality rate of 57,5%. Age, breathing rate, SPO2, non-vaccination status, HbA1C, serum glucose, D-dimer, LDH, ferritin are factors predicting mortality in SARS-COV-2 pneumonia patients with diabetes. Age and serum glucose are independent prognostic factors of mortality in these patients.

Article Details

References

Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
3. Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. J Diabetes. 2020;12(12):895-908. doi: 10.1111/1753-0407.
4. Hướng dẫn chẩn đoán viêm phổi mắc phải cộng đồng ở người lớn. LuatVietnam. Accessed August 1, 2023.
5. American Diabetes Association; 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care 1 January 2021; 44 (Supplement_1): S15- S33.
6. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7): e3319. doi:10.1002/dmrr.3319
7. Abbas AM, Fathy SK, Fawzy AT, et al. The mutual effects of COVID-19 and obesity. Obes Med. 2020;19: 100250. doi: 10.1016/ j.obmed. 2020.100250
8. Reyes LF, Murthy S, Garcia-Gallo E, et al. Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Res. 2022;8(1): 00552-02021. doi:10.1183/23120541.00552-2021
9. Abbasi E, Mirzaei F, Tavilani H,et al. Diabetes and COVID-19: Mechanism of pneumonia, treatment strategy and vaccine. Metabol Open. 2021;11: 100122. doi: 10.1016/ j.metop. 2021.100122
10. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10): 823-833. doi:10.1016/ S2213-8587(20)30271-0